Hengrui and Heyi won the first imitation of ophthalmic drugs, and 7 exclusive evaluation varieties are eye-catching!

A few days ago, the official website of CDE showed that Shijiazhuang Grey Pharmaceutical's Tobramycin eye drops, Zhongshan Wanhan Pharmaceutical's sodium bromfenac eye drops and other ophthalmic drugs were accepted

A few days ago, the official website of CDE shows that Shijiazhuang Grey Pharmaceutical's Tobramycin Eye Drops, Hunan Xianshi Pharmaceutical | Zhejiang Thermo Pharmaceutical's Sodium Hyaluronate Eye Drops and Zhongshan Wanhan Pharmaceutical's Sodium Brofenac Eye Drops were all accepted as imitations of 4 types of production, of which Tobramycin Eye Drops did not have enterprises evaluated, and Shijiazhuang Grey Pharmaceutical is expected to become the first enterprise to be evaluated.

Source: Intranet MED2.

Source: Intranet MED2.

Source: Terminal competition patternof public hospitals in key provinces and cities of The data of the intranet shows that in the first quarter of 2022, the sales of terminal ophthalmic drugs in public hospitals in key provinces and cities have risen again, with an increase of more than 7%

Source: Minnei Network key provinces and cities public hospital terminal competition patternIt is worth noting that the third batch of collection of ophthalmic drugs for the first time, as of now, levofloxacin eye drops, sodium hyaluronate eye drops, orotadine hydrochloride eye drops, moxifloxacin hydrochloride eye drops 4 varieties have been included in the collection

Source: Minnesnet key provinces and cities public hospital terminal competition patternBrand TOP10, Novartis' leizumab injection, Kanghong's Compaxipu eye injection, Bayer's Abercept intraocular injection solution ranked in the top three

Source: Mi nei network key provinces and cities public hospital terminal competition patternCompaxipu eye injection is the exclusive product of Kanghong Pharmaceutical, Intranet data show that in the first quarter of 2022, the key provincial and municipal public hospital terminal Compaxip eye injection sales climbed steadily, an increase of more than 5%